Philip Burroughs is a committed philanthropist based out of Mechanicsville, MD

Tag: research

Philip Burroughs Managing Pancreatic Cancer

Managing Pancreatic Cancer

As one of the world’s leading causes of death in the world, cancer is a terrible affliction. What’s worse, is that there is not one, but several different forms of the deadly disease, making finding a cure for each incredibly difficult. Pancreatic cancer, in particular, is the eighth most common cause of cancer-related death in the world. And although there is no sure, universal cure, there may be hope yet for those suffering from the disease.

The protein known as S100P is frequently found in pancreatic cancer patients, and essentially spreads cancer throughout the pancreas. Researchers at the University of Hertfordshire, with the help of Dr. Tatjana Crnogorac-Jurcevic of the Barts Cancer Institute, Queen Mary University of London, have potentially discovered a way to prevent the harmful protein from even being activated.

According to an article from Independent, the project, which was funded by the Worldwide Cancer Research charity, featured a bevy of scientists. In the article, two of the scientists involved in the project described the process of finding a potential cure. Apparently, Dr. Stewart Kirton of the University of Hertfordshire designed structures of new drugs based on an asthma prevention drug called Cromolyn, which were then synthesized by Dr Sharon Rossiter.

Later, the scientists used molecular biology in order to screen 93 different synthetic compounds for their ability to suppress S100P. The screening found 18 potential drugs, which were then tested for their toxicity on cancerous cells. Although the compounds did not kill the cancerous cells, they did manage to prevent migration, which is ideal for chemotherapy, as it slows down the cells, making them easier to attack.

Now, the scientists will spend the next few months looking over the most promising drugs and alter them, in an attempt to limit the amount of side-effects. The authors are hopeful that even though this breakthrough may not lead to a cure, it may make pancreatic cancer a manageable disease.

If these scientists can truly make pancreatic cancer manageable, it could affect the lives of millions the world over. More than 53,000 people are diagnosed with pancreatic cancer each year, with a staggering 43,000 dying from the disease. Hopefully this treatment can allow those suffering to have a healthier, more optimistic future.

I’ll be sure to update you should there be any breakthroughs or developments in this story.

Philip Burroughs IBM’s Watson to Study Genomics For Cancer Research

IBM’s Watson to Study Genomics For Cancer Research

One of humankind’s deadliest diseases is cancer. It is not only deadly for the amount of victims it claims, but for the fact that there is still no known cure. While certain treatments like chemotherapy can be used in the fight against this terrible affliction, they do not always succeed. That is why IBM and genetic research company Illumina are teaming up to use IBM’s Watson to take cancer head on.

Watson is a cognitive technology that was designed for the sole purpose of analyzing data and answering some of the world’s toughest questions. The two companies have come together to create Watson for Genomics. Watson for Genomics hopes to both simplify and create an industry standard for genomic data interpretation in cancer research.

Scientists who are using Illumina’s BaseSpace Sequence hub and tumor sequencing process will now be able to analyze the information collected much faster. According to an official statement from IBM, Watson for Genomics will essentially read through a breadth of academic research as well as genetic files produced by Illumina’s TruSight Tumor 170 and create a report that researchers can use in mere minutes. The TruSight Tumor 170 is a solid tumor profiling panel created to detect several variants across 170 genes.

All of this is tremendous news for cancer research. Understanding genomics is a crucial element to fighting cancer. Recent studies suggest that by understanding the genomic element of a tumor, physicians can better tailor a specific treatment to a patient, instead of applying a general treatment, which may not provide any help.

In the same statement, President and CEO of Illumina, Francis deSouza, noted his thoughts on the incredible potential of the team up. “To enable precision cancer medicine on a large scale, we need new tools to overcome the data barriers of genomic research,” said deSouza. “With a comprehensive assay of Illumina and the power of Watson, we hope to deliver a rapid turnaround of the genomic alteration results.”

As Watson continues to grow and learn, its implementation into genomic research can do wonders for cancer research. Hopefully, this team up can prove fruitful and create the long-awaited cure for cancer.

Powered by WordPress & Theme by Anders Norén